search
Back to results

Crohn's Disease Stem Cell Transplantation

Primary Purpose

Crohn's Disease

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Autologous Stem Cell Transplantation
Sponsored by
Northwestern University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Crohn's Disease

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age 18 years or older and less than age 55 years at time of pretransplant evaluation. An established clinical diagnosis of severe CD that has failed therapy with prednisone, azathioprine, 5 ASA products and metronidazole, and has failed an anti-TNF alpha inhibitor. Failure is defined as a CDAI (appendix A) 225-400. Pre-study peripheral blood counts must include a platelet count greater than 100,000/ul and an absolute neutrophil count greater than 1500/ul. In those randomized to receive the transplant, a stem cell harvest greater than 2.0 x 106 CD34 cells/kg is required. Ability to give informed consent. Exclusion Criteria: HIV positive. History of coronary artery disease, or congestive heart failure. Uncontrolled diabetes mellitus, or any other illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive chemotherapy. Prior history of malignancy except localized basal cell or squamous skin cancer. Other malignancies for which the patient is judged to be cured by local surgical therapy, such as head and neck cancer, or stage I breast cancer will be considered on an individual basis. Positive pregnancy test, lactation, inability or unwillingness to pursue effective means of birth control, failure to accept or comprehend irreversible sterility as a side effect of therapy. Psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible. FEV 1/FVC < 50% of predicted, DLCO < 50% of predicted. Resting LVEF < 40%. Bilirubin > 2.0 mg/dl, transferase (AST) > 2x upper limit of normal. Serum creatinine > 2.0 mg/dl. Platelet count less than 100,000/ul, ANC less than 1500/ul. Patients presenting with intestinal perforation or toxic megacolon, or a suppurative problem that will require urgent surgery. In addition, the patient may not have any active infection. The presence of intestinal stomas does not exclude the patient from study. Splenomegaly (palpable spleen on physical exam). Inability to collect > 2.0 x 106 CD34+ cells/kg. Positive pregnancy test.

Sites / Locations

  • Northwestern University, Feinberg School of Medicine

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Autologous Stem Cell Transplantation

Arm Description

Autologous Stem Cell Transplantation will be performed after the conditioning regimen

Outcomes

Primary Outcome Measures

Number of Participants With Remission or Clinical Improvement as Assessed by Crohn's Disease Activity Index (CDAI) Scores
Clinical remission defined as a CDAI less than 150 and clinical improvement defined as decline in CDI> or = 70 one year following entry. The participant was not assessed according to the criteria of the outcome measure, because the participant was lost for follow-up.

Secondary Outcome Measures

Full Information

First Posted
January 2, 2006
Last Updated
February 10, 2014
Sponsor
Northwestern University
search

1. Study Identification

Unique Protocol Identification Number
NCT00271947
Brief Title
Crohn's Disease Stem Cell Transplantation
Official Title
Crohn's Disease Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation (CDNST) Versus Standard Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
February 2014
Overall Recruitment Status
Terminated
Why Stopped
The PI, who was sponsor got retired
Study Start Date
April 2005 (undefined)
Primary Completion Date
April 2012 (Actual)
Study Completion Date
April 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Northwestern University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Crohn's disease (CD) is a chronic illness, immunologically mediated, probably induced by the exposure of the intestine to an antigen or antigens similar to the intestine, to which immunologic tolerance is lost or a dysregulated immunity ensues. The disease has a variable course, from a mild, intermittently active illness requiring only symptomatic therapy to a fulminant illness requiring potentially dangerous immunosuppressive therapy, surgery or both. The molecular defect causing CD has not been characterized, but probably involves aberrant T cell function. Although CD often responds to immunosuppressive medication including corticosteroids, azathioprine and 6-mercaptopurine, to anti inflammatory drugs such as 5 aminosalicylate (5 ASA), or to some antimicrobial agents, including metronidazole, no therapy has been curative. In patients with severe CD, who have been unresponsive to corticosteroids, azathioprine, 5 ASA, metronidazole, and infliximab, we propose to compare the efficacy of Crohn's disease non-myeloablative autologous hematopoietic stem cell transplantation (CDNST) to standard therapy. Subsequent disease activity will be followed by (1) Crohn's disease activity index (CDAI), (2) a more global severity index, the Crohn's Severity Index, (3) type and amount of therapy for CD, and (4) clinical, hematologic and biochemical studies.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Crohn's Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
1 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Autologous Stem Cell Transplantation
Arm Type
Experimental
Arm Description
Autologous Stem Cell Transplantation will be performed after the conditioning regimen
Intervention Type
Biological
Intervention Name(s)
Autologous Stem Cell Transplantation
Intervention Description
Autologous Stem Cell Transplantation will be performed after conditioning regimen
Primary Outcome Measure Information:
Title
Number of Participants With Remission or Clinical Improvement as Assessed by Crohn's Disease Activity Index (CDAI) Scores
Description
Clinical remission defined as a CDAI less than 150 and clinical improvement defined as decline in CDI> or = 70 one year following entry. The participant was not assessed according to the criteria of the outcome measure, because the participant was lost for follow-up.
Time Frame
baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 years or older and less than age 55 years at time of pretransplant evaluation. An established clinical diagnosis of severe CD that has failed therapy with prednisone, azathioprine, 5 ASA products and metronidazole, and has failed an anti-TNF alpha inhibitor. Failure is defined as a CDAI (appendix A) 225-400. Pre-study peripheral blood counts must include a platelet count greater than 100,000/ul and an absolute neutrophil count greater than 1500/ul. In those randomized to receive the transplant, a stem cell harvest greater than 2.0 x 106 CD34 cells/kg is required. Ability to give informed consent. Exclusion Criteria: HIV positive. History of coronary artery disease, or congestive heart failure. Uncontrolled diabetes mellitus, or any other illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive chemotherapy. Prior history of malignancy except localized basal cell or squamous skin cancer. Other malignancies for which the patient is judged to be cured by local surgical therapy, such as head and neck cancer, or stage I breast cancer will be considered on an individual basis. Positive pregnancy test, lactation, inability or unwillingness to pursue effective means of birth control, failure to accept or comprehend irreversible sterility as a side effect of therapy. Psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible. FEV 1/FVC < 50% of predicted, DLCO < 50% of predicted. Resting LVEF < 40%. Bilirubin > 2.0 mg/dl, transferase (AST) > 2x upper limit of normal. Serum creatinine > 2.0 mg/dl. Platelet count less than 100,000/ul, ANC less than 1500/ul. Patients presenting with intestinal perforation or toxic megacolon, or a suppurative problem that will require urgent surgery. In addition, the patient may not have any active infection. The presence of intestinal stomas does not exclude the patient from study. Splenomegaly (palpable spleen on physical exam). Inability to collect > 2.0 x 106 CD34+ cells/kg. Positive pregnancy test.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Craig, MD
Organizational Affiliation
Northwestern University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Northwestern University, Feinberg School of Medicine
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Crohn's Disease Stem Cell Transplantation

We'll reach out to this number within 24 hrs